A 90-day in-country feeding trial in Wistar rats was conducted at Tianjin Laboratory in China to assess toxicity of diets containing DAS-44406-6 soybean meal. There were no treatment-related changes observed when compared with the non-GM isoline control groups but histopathologically, 2 of 10 high-dose females were reported to show kidney lesions. However, these findings contrasted with the absence of any treatment-related kidney lesions in 3 separate 90-day toxicity studies previously conducted in Sprague Dawley rats. Strain difference is not expected in the kidney response, and based on the low incidence and contrary evidence from previous studies, it is likely that these lesions were of spontaneous origin, or artefactual. To determine that the lesions observed were not treatment-related in Wistar rats, a specific follow-up confirmatory study was conducted under Good Laboratory Practices (GLP) in the Wistar strain of rats following an identical study design to the Tianjin study. To increase the power of detecting effects, twice the number of animals per group (20/sex/group) were used, and no treatment-related kidney histopathological changes were observed. Based on these results and entire weight of evidence evaluation, it is concluded that the histopathological changes previously noted in the 2 female Wistar rats of Tianjin study were not treatment-related and that DAS-44406-6 soybeans are as safe as conventional non-GM soybeans.
Introduction
Subchronic toxicity studies in rats are often conducted to evaluate the safety of novel foods derived from genetically modified (GM) crops. However, whole-food animal feeding studies have been widely criticized as being of very low value in the safety assessment of GM crops (Bartholomaeus et al., 2013; Project GRACE, 2014; Devos et al., 2016) . To date, no evidence of adverse effects has been revealed in these rodent studies (NAS, 2016; Hong et al., 2017) . Certain countries have specific data requirements for the safety assessment of GM crops with some requiring in-country field trials and feeding trials. Chinese Regulatory authority Ministry of Agriculture (MoA) requires applicants to conduct 90-day feeding studies locally in China according to the Chinese National Standard (Chinese Standard NY/T1102-2006 which differs from the OECD 408 test guideline (OECD 408) in certain aspects of the study design.
Transgenic DAS-44406-6 soybean was co-developed by Dow AgroSciences (Indianapolis, IN, USA) and MS Technologies (West Point, IA, USA), and expresses the aryloxyalkanoate dioxygenase-12 (AAD-12), 2mEPSPS, and phosphinothricin acetyltransferase (PAT) proteins that confer tolerance to 2,4-dichloropheoxyacetic acid (2,4-D), glyphosate, and glufosinate-ammonium herbicides, respectively (Cui et al., 2014) . DAS-44406-6 soybean has regulatory approval for cultivation and food/feed use in the United States, Canada, Argentina, and Brazil, and has also been approved for food and feed use in Australia, Colombia, Japan, Mexico, New Zealand, South Africa, South Korea, and Taiwan (ISAAA, 2017a) . A breeding stack with a transgenic insect-resistant soybean with insect resistance has been developed as well (ISAAA, 2017b) .
As part of the abovementioned in-country feeding study requirement, Tianjin Centers for Disease Control and Prevention Laboratory in China conducted a 90-day rat toxicity study (referred to as initial study in the report) assessing the safety of DAS-44406-6 soybean. Ten male and female Wistar Han rats were given diets formulated with DAS-44406-6 toasted soybean meal (7.5, 15, or 30%w/w) or equivalent amounts of a near isoline conventional control soybean meal, Maverick, https://doi.org/10.1016/j.yrtph.2017.11.016 Received 5 October 2017; Received in revised form 22 November 2017; Accepted 27 November 2017 for 90 days. While, no treatment-related adverse effects were reported in feed consumption, body weight gains, hematology, serum chemistry, organ weights, or gross pathological observations, microscopically, there were two females in the high dose group that were reported to exhibit kidney lesions. Even though the incidence was low and contrary to three previously conducted 90-day toxicity studies using Sprague Dawley rats (EFSA, 2017; Papineni et al., 2017a , Papineni, et al., 2017b , a follow-up confirmatory study was conducted in Wistar Han rats at Charles River Laboratory (USA) with an identical study design as Tianjin study but twice the number of animals per sex per group to determine whether the microscopic kidney lesions observed in the two high dose females were treatment-related. Results from the initial Tianjin laboratory study and the follow-up confirmatory study using Wistar rats are reported and discussed here.
Materials and methods

Animals
The initial and the follow-up confirmatory feeding studies were conducted at Tianjin (China) and Charles River Laboratories (USA), respectively. The initial study used Wistar Han rats from Beijing Vital River Laboratory Animal Technology Co. Ltd., while the confirmatory study used Wistar Han rats from Charles River Laboratories, Inc. (Raleigh, NC). Rats were housed singly in the initial study and in groups of two per cage in the confirmatory study. Animal rooms were maintained at a temperature of 20°C-26°C and a relative humidity at 30%-70%.
Food and water
Rats were provided water and diet ad libitum throughout the studies. Diets used in the initial study were prepared by Beijing HFK BioSciences., Ltd and met standard GB 14924.3-2001 "Laboratory animals -Mice and rat formula feeds." In the confirmatory study, rats were fed Certified Rodent LabDiet ® 5002 meal prepared by PMI Nutrition International, LLC.
Study design
Treatment groups in the initial study contained ten animals per sex, while treatment groups in the confirmatory study contained twenty animals per sex. The test design for both studies included groups fed the standard basal diet, a control group fed diets with 7.5, 15 and 30% near isoline soybean meal (formulated in accordance with basal diet) and a treatment group fed with 7.5, 15 and 30% DAS-44406-6 soybean (formulated in accordance with basal diet (Table 1) ).
Clinical observations
Food consumption and body weights were recorded weekly. Cageside observations were performed each day throughout the studies for mortality and morbidity. Clinical observations were performed on all rats once daily during the treatment period and depending on the study, included observations of changes in the skin, fur, eyes, and mucous membranes; respiratory, circulatory, autonomic, and central nervous system function; and somatomotor activity and behavior patterns. In the confirmatory study, detailed physical examinations were performed on all rats once weekly throughout the study and included removal of the rat from the home cage and placement in a standard arena for observations of changes in gait, posture, clonic or tonic movements, stereotypies (e.g., excessive grooming, repetitive circling), bizarre behavior (e.g., self-mutilation, walking backwards), and permanent or semi-permanent signs, such as skin lesions and hair loss.
Hematology and coagulation
For the initial study, red blood cell (RBC) count, hemoglobin (HGB) concentration, platelet (PLT) count, and white blood cell (WBC) count were performed in the middle and at the end of the study using blood collected via retro-orbital bleeding. Samples were analyzed using a Sysmex XT-2000i Hematology Analyzer. For the confirmatory study, whole blood for hematology evaluation was collected via the jugular vein and analyzed for RBC count, WBC count, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets (PLT), reticulocyte count, percent (RETIC), absolute (RETIC Absolute), differential leukocyte count [percent and absolute neutrophil (NEU), lymphocyte (LYMPH), monocyte (MONO), eosinophil (EOS), basophil (BASO), large unstained cell (LUC)], red cell distribution width (RDW), platelet estimate, and red cell morphology (RBC Morphology). Analysis was performed using a Bayer ADVIA ® 120
Hematology Analyzer (Siemens Healthcare Diagnostics). Coagulation parameters were not evaluated in the initial study but were evaluated in the confirmatory study. Whole blood for coagulation evaluation was collected from the jugular vein into tubes containing sodium citrate and analyzed for prothrombin time (PT) and activated partial thromboplastin time (APTT). Analysis was performed using a STAGO STA Compact Coagulation Analyzer (Diagnostica Stago).
Serum chemistry
Serum was analyzed for albumin, total protein, total bilirubin, urea nitrogen, creatinine, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, total cholesterol, and triglycerides in both studies. In the initial study, lactate dehydrogenase was also measured. In the confirmatory study, globulin [by calculation], albumin/globulin ratio [by calculation], gamma glutamyltransferase, calcium, chloride, phosphorus, potassium, and sodium were also measured. Analysis was performed in the initial study using a Toshiba TBA-40FR Chemistry Analyzer and in the confirmatory study using an ADVIA ® 1800 Serum Chemistry Analyzer (Siemens Healthcare Diagnostics).
Urinalysis
In the Tianjin study, urine samples were collected for two hours at the end of the study and inspected for color (COL), and clarity (CLA). The urine was analyzed for specific gravity (SG), pH, urobilinogen (URO), protein (PRO), glucose, ketones (KET), bilirubin (BIL), occult blood (BLD), leukocytes (LEU), and nitrites (NIT). Analysis was Z. Qian et al. Regulatory Toxicology and Pharmacology 92 (2018) 152-164 performed using RUIKE Urine Chemistry Analyzer (Changchun Ruike Medical Technology Co., Ltd, Changchun, China). In the confirmatory study at Charles River, urine samples were collected overnight at the end of the study and inspected for total volume (TVOL), color (COL), and clarity (CLA). The urine was centrifuged, and urine sediment was evaluated microscopically. The urine was analyzed for specific gravity (SG), pH, urobilinogen (URO), protein (PRO), glucose, ketones (KET), bilirubin (BIL), occult blood (BLD), leukocytes (LEU), nitrites (NIT), protein (Urine PROTEIN), glucose (Urine GLUCOSE), creatinine (Urine CREAT), and osmolality. Analysis of these parameters in the confirmatory study was performed using a Siemens Clinitek Atlas ® Automated Urine Chemistry Analyzer (Siemens Healthcare Diagnostics, Inc.)
Gross necropsy and histopathology
In both studies, animals were anesthetized and euthanized at the end of the study. Necropsy included examination of the external surface, all orifices and the cranial, thoracic, abdominal and pelvic cavities, including viscera. The following organs were weighed in both studies: adrenal glands, heart, kidneys, liver, spleen, testes (male), and thymus. In addition, in the confirmatory study, brain, epididymides (male), ovaries with oviducts (female), pituitary, prostate with seminal vesicles (male), thyroid with parathyroids, and uterus (female) were also weighed.
The tissues from all animals were collected, preserved, trimmed, embedded in paraffin, sectioned, mounted on glass microscope slides, and stained with hematoxylin and eosin. The following tissues were examined microscopically in both studies: adrenal glands, brain, epididymides (male), duodenum, jejunum, ileum, heart, kidneys, liver, lungs, ovaries (female), prostate (male), spleen, testes (male), thymus, thyroid, and uterus (female), In addition, in the confirmatory study, the following tissues were also microscopically examined: aorta, bone with marrow, (sternum, femur), cervix (female), eyes with optic nerves, esophagus, stomach, cecum, colon, rectum, larynx, lymph nodes (axillary, mesenteric, and mandibular), pancreas, peripheral nerve, Peyer's patches, pharynx, pituitary, mandibular salivary glands, seminal vesicles (male), skeletal muscle (rectus femoris), skin (with mammary gland for female), spinal cord (cervical, lumbar, and thoracic), tongue, trachea, urinary bladder, vagina (female), and gross lesions.
Statistical analysis
For the initial study, continuous data were compared using ANOVA, and frequency data were compared using a Chi-square test (alpha = 0.05).
In the confirmatory study, body weight, body weight changes, cumulative body weight change, food consumption, clinical pathology, and organ weights (absolute and relative) were subjected to statistical analysis. Because animals were socially housed sharing a common food source, the experimental unit for food consumption was the cage and the average value per cage was the dependent variable in the statistical analysis. Each analysis endpoint was analyzed, by study day and sex, with an ANOVA including treatment group as the fixed effect. All seven groups were included in the ANOVA. If a treatment group was significant at the 0.05 alpha level, the following pairwise comparisons were conducted using the mean square error from the seven group ANOVA: comparing all treatment groups to the basal diet (Dunnett's test); and comparing each of the three dose groups fed the diet containing DAS-44406-6 soybean with the corresponding dose group containing the near isoline conventional control soybean (adjusting for multiple comparisons with a modified Bonferroni adjustment of √k where k = 3 comparisons). Each pairwise comparison was evaluated at the 0.05 alpha level.
Results
Mortality
There were no test substance related deaths. No animals died in the initial study. In the confirmatory study, two females were found dead prior to study termination. One female rat from the 7.5% DAS-44406-6 group was found dead on study day 52. The likely cause of death for this animal was consistent with acute trauma as microscopic findings included acute hemorrhage around the olfactory bulb of the brain, tongue, and salivary gland. One female in the 15% DAS-44406-6 group was found dead on study day 94 (scheduled necropsies during study week 13 ranged from day 91-95 of the study). The cause of death was attributed to the jugular blood collection procedure as the animal died after phlebotomy and had macroscopic findings of dark red skeletal muscle on the ventral neck.
Detailed clinical and cage-side observations
No clinical observations attributed to the test substance were noted in any of the groups in either study.
Body weights/body weight gains/feed consumption
In the initial study, there were no statistically significant differences in mean body weights (Figs. 1 and 2), body weight gains (data not shown), or feed consumption (data not shown) when compared with the control groups. The differences observed were not considered biologically meaningful.
In the confirmatory study, no biologically significant differences were noted in mean body weights. Mean body weights were statistically lower for the 30% DAS-44406-6 treated females when compared with the basal-diet group during study week 10. This statistically significant Basal diet control group 7.5% DAS-44406-6 group 15% DAS-44406-6 group 30% DAS-44406-6 group 7.5% near-isogenicnontransgenic control group 15% near-isogenicnontransgenic control group 30% near-isogenicnontransgenic control group 
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Regulatory Toxicology and Pharmacology 92 (2018) 152-164 difference was not considered adverse or related to the diet, as the change was transient; the difference in mean body weights was small (≤6% difference); the values were similar to the corresponding nearisogenic non-transgenic control group, and the change was not dose responsive. No biologically significant differences were noted in mean body weight gains. Mean body weight gains were statistically lower, when compared with the basal-diet group, for the 15% DAS-44406-06 males during study week 0-1 and for the 30% DAS-44406-6 females during study weeks 0-1 and 8 to 9. Mean body weight gains were statistically higher, when compared with the basal-diet group, for the 7.5% DAS-44406-6 males during study weeks 4-5 and for the 30% DAS-44406-6 males during study weeks 4-5 and 12 to 13. These statistically significant differences were not considered adverse or related to the diet, as the changes were transient; the differences were small and did not result in differences in mean body weights, and the changes were not dose responsive. Additionally, the values were similar to the corresponding near-isogenic non-transgenic control group. There were no biologically significant differences noted in food consumption. During study week 3-4, food consumption for the 15% DAS-44406-6 females was statistically higher when compared with the basal-diet group. This was not considered to be adverse or related to the diet, as the change was transient; the difference was small and did not correlate with changes in body weights, and the change was not dose responsive (Figs. 3 and 4)
Hematology and coagulation
In the initial study, there were no biologically meaningful or treatment-related hematological or coagulation differences among test groups. At the midpoint of the initial study, for male animals, percent eosinophil results for the 15% isoline male group were higher than for the basal-diet group; percent basophils for the 15% DAS-44406-6 group were higher than the basal-diet group; percent monocytes for the 7.5% DAS-44406-6 group were higher than the 7.5% isoline group; percent eosinophil in the 15% DAS-44406-6 group were lower than the 15% isoline group, and hemoglobin results in the 30% DAS-44406-6 group were lower than the 30% isoline group (alpha = 0.05). For female animals, percent lymphocytes for the 7.5% DAS-44406-6 group were lower than the 7.5% isoline group. At the end of the study, there were no statistically significant differences for males or females between the basal-diet groups and any other treatment group (Tables 2 and 3 ). All results were within normal ranges, and differences were not considered biologically meaningful.
In the confirmatory study, no biologically significant differences were noted in mean hematology (Tables 4 and 5 ) or coagulation parameters (data not shown). The following statistically significant differences were found when the DAS-44406-6 groups were compared with the corresponding basal-diet group: mean HGB and RBC values were higher for the 7.5% DAS-44406-06 females during study week 7; mean PT and reticulocytes were statistically significantly higher for the 15% DAS-44406-06 females during study week 13, and mean reticulocytes were higher for the 30% DAS-44406-06 females during study week 13. These differences were not considered to be adverse or related to the diet, as the changes were small in magnitude; the values were similar to the corresponding near-isogenic non-transgenic control group, or the change was not dose responsive. Basal diet control group 7.5% DAS-44406-6 group 15% DAS-44406-6 group 30% DAS-44406-6 group 7.5% near-isogenicnontransgenic control group 15% near-isogenicnontransgenic control group 30% near-isogenicnontransgenic control group Basal diet control group 7.5% DAS-44406-6 group 15% DAS-44406-6 group 30% DAS-44406-6 group 7.5% near isogenic nontrangenic control group 15% near isogenic nontrangenic control group 30% near isogenic nontrangenic control group 
Clinical chemistry
In the initial study, there were no treatment-related effects on clinical chemistry parameters. At the midpoint of the study, the results for male animals for lactate dehydrogenase in the 30% DAS-44406-6 group were statistically lower than the 30% isoline group. At the end of the study, for male animals, glucose for the 15% DAS-44406-6 group was statistically higher than for the 15% isoline group. These results fell within the normal ranges and were not considered biologically meaningful, due to the transient nature of the findings and/or lack of doseresponse relationship.
In the confirmatory study, no biologically significant differences were noted in mean serum chemistry parameters. The following statistical significance was noted when the DAS-44406-6 groups were compared with the basal-diet group: mean albumin values were lower for the 30% DAS-44406-6 females during study weeks 7 and 13; mean ALP was higher for the 15 and 13% DAS-44406-6 females during study week 7; mean ALT was higher for the 15% DAS-44406-6 females during study week 7; mean cholesterol was higher for the 7.5 and 15% DAS-44406-6 males during study week 7; mean phosphorus was higher for the 7.5% DAS-44406-6 males during study weeks 7 and 13 and for the 15% DAS-44406-6 males during study week 7; potassium was lower for the 15 and 30% DAS-44406-6 males during study week 7; total protein was lower for the 30% DAS-44406-6 females during study weeks 7 and 13, and urea nitrogen was higher for the 15% DAS-44406-6 males during study week 7 and for the 7.5, 15, and 30% DAS-44406-6 females during study week 13. These differences were not considered to be adverse or related to the diet, as the changes did not correlate to microscopic findings, were small in magnitude; values were similar to the corresponding near-isogenic non transgenic control group, and/or the changes were not dose responsive (Tables 6-8) 3.6. Urinalysis Urinalysis was conducted in both studies, and no statistically significant differences were noted in urinalysis parameters when the DAS-44406-6 groups were compared with the basal-diet group in either study. (Table 9 ).
Organ weights
In the initial study, differences in organ weights and relative organ weights of male and female animals did not differ between the basaldiet group and any test group.
In the confirmatory study, no biologically significant differences were noted in mean organ weights. Mean seminal vesicle with prostrate weights along with tissue to brain weights were statistically significant when the 7.5% DAS-44406-6 group was compared with the basal-diet group. This difference was not considered to be adverse or related to the diet, as the change was not dose responsive; the basal-diet group value was unusually low, and the values were similar to the corresponding near-isogenic non transgenic control group (Tables 10-14 Basal diet control group 7.5% DAS-44406-6 group 15% DAS-44406-6 group 30% DAS-44406-6 group 7.5 % near isogenic nontrangenic control group 15% near isogenic nontrangenic control group 30% near isogenic nontrangenic control group Fig. 4 . Confirmatory Study. Mean weekly body weights of female rats. 
Gross pathology and histopathology
There were no gross or histopathologic changes in either study that could be attributed to treatment. In the initial study, glomerular volume enlargement in two female animals was reported in the 30% DAS-44406-6 group, along with basophilic lesions and necrosis of epithelial cells in renal tubules with interstitial lymphocyte infiltration; however, other pathological changes were absent. Similar kidney lesions have been historically observed in both male and female rats in the 90-day rat feeding studies conducted in this laboratory in the past five years (data not shown due to administrative restrictions at the laboratory).
In the confirmatory study, there were no treatment-related gross and histopathological changes; the changes observed were considered to be incidental findings. The main incidental findings were occasional basophilic tubules consistent with spontaneous chronic progressive nephropathy (CPN) in males and females, and non-treatment-related mineralization at the junction of the outer and inner stripes of outer medulla of female rats. However, there was no change in the prevalence, severity, or histologic character of the incidental tissue alterations compared with either the basal-diet group or the near-isogenic non-transgenic control group.
Discussion
GM crops have been commercialized since the 1990's for use in human food and animal feed and undergo rigorous safety evaluation. Safety considerations begin at the level of DNA with characterization of the genetic modification to evaluate any unintended changes, followed by safety of the proteins relative to toxicity, allergenicity, and environmental exposure. Grain is also evaluated for its nutritional value and any unintended effects. To date, no evidence of adverse effects have been observed in the 90-day feeding studies conducted with GM crops, nor have any adverse effects been reported with any of the transgenic proteins expressed in these GM crops (Bren, 2003; Bartholomaeus et al., None significantly different from control group. a n = 18. b n = 20.
2013; NAS, 2016; Project GRACE, 2014; Hong et al., 2017) . No adverse effects were reported in the initial study following dietary administration of the DAS-44406-6 soybean meal to Wistar Han rats, except for kidney histopathological changes in two high dose females (2/20 total rats). However, the renal histopathology observed in two Wistar rats contrasted with the absence of any treatment-related kidney histopathologic changes in the three 90-day studies conducted previously with the same event in Sprague-Dawley rats (EFSA, 2017; Papineni et al., 2017a , Papineni, et al., 2017b . Thus, based on the lack of confirmatory evidence from three existing studies, the low incidence with only two animals affected, and the known predisposition of rat kidney to spontaneous lesions and/or histological artifacts, the evidence was insufficient to attribute the finding to the treatment. To definitively determine if these lesions were treatment-related, a confirmatory study was conducted under GLP standards following an identical study design as the initial study. In addition, three reference commercial-variety soybean groups and a standard rodent chow group were included for context (results not reported). Twice the number of animals per group were used compared with the initial study to increase the power of the experiment to detect any treatment-related effects. Consistent with the results of the previous feeding studies in Sprague-Dawley rats, no treatment-related adverse effects, including kidney histopathological changes, were seen in the follow-up study conducted in Wistar Han rats, suggesting that the kidney histopathological lesions observed in the initial study in two females were not related to treatment. However, A weight of evidence (WoE) analysis was conducted using the globally accepted modified Bradford Hill criteria (Hill, 1965) to evaluate strength, consistency, specificity, coherence, and biological plausibility of multiple lines of evidence to establish the cause and effect relationship between DAS-44406-6 11.3 ± 1.92 10.8 ± 1.16 11.1 ± 1.66 11.5 ± 1.44 11.1 ± 1.1 10.8 ± 0.84 11.2 ± 1.84 * = Significantly different from the control group at 0.05 using Dunnett's test. ** = Significantly different from the control group at 0.01 using Dunnett's test. a n = 17. b n = 18. c n = 20.
Table 6
Initial study: Summary of serum biochemistry (c ± V). 35.9 ± 2.4 51.9 ± 11.9 30% Isoline 10 24.5 ± 5.9 71.9 ± 9.2 54.5 ± 2.7 35.5 ± 2.0 59.5 ± 13.8 7.5% DAS-44406-6 10 24.7 ± 5.7 68.3 ± 12.9 54.3 ± 1.8 36.2 ± 1.7 55.5 ± 13.9 15% DAS-44406-6 10 21.2 ± 4.8 72.8 ± 12.5 55.6 ± 2.0 36.5 ± 1.4 56.7 ± 10.9 30% DAS-44406-6 10 22.5 ± 3.5 66.2 ± 13.9 56.6 ± 2.5 37.3 ± 2.1 52.2 ± 13.0
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Biological plausibility
The transgenic proteins (AAD_12, 2mEPSPS, or PAT) expressed have a specific intended mode of action and are also expressed in other crops that are either deregulated by regulatory authorities or currently commercialized and therefore have been thoroughly evaluated for safety and have been found to have no safety concerns (US-FDA, 2011; US-FDA, 2013; US-FDA, 2014; Hérouet et al., 2005 , Hérouet et al., 2009 EPA, 1995; EPA, 1997; OECD, 1999) . Moreover, the transformation process did not cause compositional changes for DAS-44406-6 soybean, nor were any adverse effects observed in animals fed DAS-44406-6 soybean (Hill et al., 2017; Lepping et al., 2013) .
Thus, there is no evidence from the molecular characterization of the event, mode of action of the expressed proteins, bioinformatics analysis, allergenicity assessment, toxicology data on the proteins, nor crop-composition analysis suggesting a plausible hypothesis for DAS-44406-6 to induce kidney changes recorded in the Tianjin study.
Evaluation of coherence
The fact that this finding occurred only in female rats is unusual, as male rats are often more prone to chemically-induced toxic alteration than female rats (Trevisan et al., 2012) . Male rats tend to have a predisposition for higher accumulation of toxic agents in the kidney, whereas female rats tend towards a higher renal clearance of chemical agents (Sabolic et al., 2007) . Such male and female disparity is believed to be related to gender differences in sex hormone-regulated expression and function of specific renal transporters in the proximal tubule cells of rat cortex and outer stripe of outer medulla (OSOM) (Sabolic et al., 2007) .
Evaluation of specificity
Historical control incidence
It is important to note that the kidney lesions described in the initial study in female rats were historically observed in the same Laboratory in the control Wistar rats in the 90-day studies conducted in the past five years. This evidence of historical control incidence strongly suggests that the kidney lesions are not specific to DAS-44406-6 soybean diets. In addition, alternative or other confounding factors that could be contributing to these effects cannot be ruled out and are discussed below to understand the specificity.
Confounding factors 7.2.1. Common lesions of spontaneous origin in rat kidney
The most common spontaneous lesions occurring in 90-day studies in all of the widely-used strains of rat (Fisher 344, Sprague-Dawley, and Wistar) are chronic progressive nephropathy (CPN), a disease that progresses to end-stage kidney in old age (Frazier et al., 2012; Hard and Khan, 2004) , and focal mononuclear cell infiltration in the cortex or OSOM.
CPN is a significant confounding factor for interpretation of renal histopathology in subchronic and chronic toxicity and carcinogenicity studies (Wolf and Mann, 2005) . It commences at an early age, often by 6-7 weeks and can be present as solitary basophilic tubules in up to 100% of test animals in 90-day studies at grades of minimal to mild (on a severity scale of 1-4, referring to minimal, mild, moderate and marked) (Travlos et al., 2011) . Although it is more predominant in males, female rats are also affected by CPN. In the early stages, the disease is characterized by foci of tubule basophilia in the cortex, associated with basement membrane thickening. The basophilic tubules can contain sporadic cells undergoing single cell necrosis and compensatory, regenerative mitotic activity (Hard and Khan, 2004; Hard et al., 2009) . It should also be recognized that the nature and intensity of staining of CPN basophilic tubules can vary between animals and between studies; affected tubules may be barely perceptible in some studies, and conspicuous in others. Basophilic tubules are commonly recorded as spontaneous findings in all exposure groups of 90-day toxicity studies in rats; these are invariably tubules involved in the early stages of CPN. Some chemicals/agents can exacerbate CPN leading to a dose-related increase in CPN-related basophilic tubules in subchronic and chronic studies, but this was not the case with DAS-44406-6.
Mononuclear cell infiltration of cortex or OSOM is a focal change involving aggregates of small cells, usually lymphocytes (Frazier et al., 2012) , in the interstitium often near arcuate arteries or other renal blood vessels. These aggregates are not usually associated with any degenerative tubule change, but focal lesions of CPN can also be accompanied by a mild infiltration of mononuclear cells in the Table 7 Initial study: Summary of serum biochemistry (c ± V) (Cont). interstitium.
Artefactual changes in rat kidney
Artefacts encountered in histopathology of laboratory animals in general, as well as in kidney, are described by McInnes (2012) and Bindhu et al. (2013) . McInnes (2012) places particular emphasis on artefacts caused by fixation deviations. The kidney is predisposed to artefactual change during necropsy and subsequent histological processing, with nuclei and other organelles rupturing into the tubule lumen as agonal changes when the blood supply is severed (Longley and Burstone, 1963; Griffith et al., 1967) . One of the most common causes of artefact in the rodent kidney is a delay in placing the kidneys 78 ± 7.6 74 ± 10.1 80 ± 12.9 77 ± 10.5 84 ± 28 86 ± 27.8 81 ± 15.7 GGT (U/L) 0 ± 0 0 ± 0 0.5 ± 2.24 0 ± 0 0 ± 0 0 ± 0 0 ± 0 Glucose (mg/dL) 92 ± 12.2 96 ± 8.6 93 ± 9.1 94 ± 11.1 98 ± 10 92 ± 11.1 95 ± 9.5 Cholesterol (mg/dL) 62 ± 11 77.** ± 12. 106 ± 1.9 105 ± 1.9 106 ± 1.2 107 ± 1.6 106 ± 1.5 106 ± 1.5 106 ± 1.5 Phosphorus (mg/dL) 6 ± 0.97 6.5 ± 0.8 6.5 ± 1.21 6 ± 0.92 7.1** ± 1.11 6.6 ± 1.06 6.5 ± 1. Females (Week 13) * = Significantly different from the control group at 0.05 using Dunnet's test. ** = Significantly different from the control group at 0.01 using Dunnet's test.
Table 9
Initial Study: Urinalysis values for male and female rats (mean ± SD).
Control
Isoline-Low Isoline-Mid Isoline-High DAS-44406-6-Low DAS-44406-6-Mid DAS-44406-6-High n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 into formalin fixative. The result can be a subcapsular effect of rarefied and disintegrated tubule cells for the outermost 3 or 4 tubules. In addition, focal autolytic change can be noted in the OSOM, and sometimes in the cortex. There are instances where such a focal autolytic change can be mistaken for confluent proximal tubule cell necrosis.
Consistency of the effect
Three subchronic toxicity studies in Sprague Dawley rats were conducted previously under rigorous standards evaluating DAS-44406-6 soybeans (EFSA, 2017; Papineni et al., 2017a , Papineni, et al., 2017b to fulfil the evolving requirements of EFSA. No treatment-related clinical chemistry, organ weight or histopathological changes were reported in kidneys suggesting that there is no consistency in the effects observed and thus these effects are unlikely to be treatment-related.
Reproducibility of the effect
Reproducibility is one of the key criteria to establish causal relationship and was investigated by conducting a confirmatory study following the same study design but with more number of animals per group to increase the sensitivity of the study to detect effects. The kidney lesions were not observed in the follow-up study, suggesting that the observations in the initial study with Wistar rats were unrelated to treatment. The confirmatory study with 20 female Wistar rats had 90% power to detect the lesions reported in 2 of 10 females, based on a Fisher's Exact Test comparing the frequencies of occurrence in the two studies (2/10 vs. 0/20; P-value = 0.10). If one considers the additional 16 female Sprague Dawley rats from the previous 90-day study also fed with diets containing 30% DAS-44406-6 soybean (Papineni et al., 2017b) , the total number of female rats with no kidney lesions is 36 rats, suggesting that such a finding has a 4% chance of occurrence if both are random samples from an underlying distribution (2/10 vs 0/ 36; P-value = 0.04). If one further considers that male rats are more prone to chemically-induced toxic alteration of the kidney than females and includes males fed diets containing 30% DAS-44406-6 in the calculations, then the chances of the kidney lesions being treatment-related is negligible (10 male Wistar rats in the initial study, 40 Wistar rats in the confirmatory study, plus 32 Sprague Dawley rats in the previous study; 2/10 vs. 0/82; P-value = 0.01).
Conclusions
In conclusion, based on the WoE analysis below following the principles of the globally accepted Bradford Hill criteria to establish causal relationship between treatment and an effect, the renal lesions reported in female Wistar rats in the initial study are not considered to be treatment-related.
• Low incidence (2/20 total rats) of adverse alterations recorded in Regulatory Toxicology and Pharmacology 92 (2018) 152-164 only female Wistar rats (initial Tianjin study) is not strong evidence to establish a cause and effect relationship.
• Historical control incidence of these observations in the Tianjin laboratory and predisposition of rat kidneys to other confounding factors such as CPN or fixation artefacts suggests lack of specificity of the effect.
• Absence of kidney lesions in three similar studies in Sprague-Dawley rats suggests lack of consistency of the evidence.
• Evaluation of the mode of action of introduced proteins and crop compositional study showing lack of composition changes suggests that there is no biologically plausible mechanism for DAS-44406-6 to induce kidney lesions.
• Most convincingly, the follow-up confirmatory study in Wistar Han rats (as reported here) did not show any treatment-related kidney changes, suggesting lack of reproducibility. Based on the weight of evidence, it can be concluded that the kidney observations in the initial study were spontaneous or artefactual and not treatment-related, and that DAS-44406-6 soybeans are as safe as non-GM soybeans.
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